-
Geron: From Launch Hype To Later-Line Gravity
19 Dec 2025 19:18 GMT
Summary
Geron remains a Sell as RYTELO … ;DigitalVision via Getty Images Introduction Geron’s stock (GERN) has … in May. Recall that Geron markets RYTELO in myelodysplastic syndrome … stocks by evaluating clinical data, treatment guidelines, and market dynamics. …
-
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Dec 2025 21:30 GMT
… , 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial … to continued employment with Geron through the applicable vesting … under the plan. About Geron
Geron is a commercial-stage … European Union for the treatment of certain adult patients …
-
Praxis tees up another approval filing; Geron turns to layoffs
12 Dec 2025 19:05 GMT
… Geron, as well as updates from Rhythm Pharmaceuticals and Centessa Pharmaceuticals … relutrigine, as a potential treatment for a group of … — Ben Fidler
Rhythm Pharmaceuticals will advance its drug … with developers like Takeda Pharmaceutical and Alkermes to …
-
Geron cuts one-third of staff, focusing on turning Rytelo launch around
11 Dec 2025 20:59 GMT
-
Rx Rundown: Pfizer, Mirum Pharmaceuticals, Novartis and more
11 Dec 2025 22:38 GMT
… lymphoma who have failed treatment with or relapsed … end of the year.
Geron will reduce its workforce … after 36 weeks of treatment.
The Advisory Committee on … treatment combo improved outcomes in relapsed/refractory myeloma.
Veterinary compounding pharmacy …
-
Geron to lay off 3rd of workforce in bid to slash operating costs
11 Dec 2025 20:43 GMT
… executive roster throughout 2025—Geron Corporation is scaling back its … and $260 million.
The pharma noted that it expects … myelofibrosis.
Semerjian added that Geron is also “exploring opportunities … the way out at Geron. Geron immediately tapped a replacement …
-
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
11 Dec 2025 13:00 GMT
… 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- … European Union for the treatment of certain adult … Geron is successful in commercializing RYTELO (imetelstat) for the treatment … efficacy results of RYTELO treatment cause its benefit- …
-
After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing
12 Nov 2025 20:40 GMT
… dedicated to examining how pharma executives and other leaders … telomerase inhibitor blood cancer treatment Rytelo. When it finally … PharmaVoice.
But Geron soon learned that launching a promising treatment … for brevity and style.
PHARMAVOICE: What has been …
-
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
05 Nov 2025 12:47 GMT
… imetelstat clinical response rates and treatment-emergent cytopenias.
Clinical Pipeline
Completed … CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Geron Corporation
Copyright Business Wire 2025 …
-
GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
23 Oct 2025 22:14 GMT
… Who Suffered Losses In Geron (GERN) To Contact … long-term stockholder of Geron securities between February 28, … is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf … board of directors of Geron have breached their fiduciary …
About
© 1995-2025